Curcumin mono-carbonyl analogs as potent antibacterial compounds: Synthesis, biological evaluation and docking simulation study

The present study aims to synthesize, evaluation of biological activity, and study docking of new analog compounds A01, B01, C01, and C02 as antibacterial. Claisen-Schmidt method used to synthesize A01, B01, C01, and C02 compounds. The new analog compounds A01, B01, C01, and C02 have antibacterial activity with IC<inf>50</inf> values of 37.1µM, 140µM, respectively; 79µM and 117µM in the aureus; 56.6µM, 282µM, 97.6µM and 186.1µM in subtilis; 291.2µM, 1025.9µM, 679.81µM and 561.9µM in E.coli; 29.5µM, 310.5µM, 32.9µM and 130.6µM in P. aeruginosa; 66.6µM, 328.6µM, 49.3µM and 253.8µM in mutans; 97.2 µM, 392.2 µM, 129.6 µM, and 191.6 µM in faecialis; 44,811µM (A113) in C.albicans. Synthesized mono-carbonyl curcumin analog compounds have antibacterial activity through inhibition of bacterial cell wall synthesis. © 2020 Elsevier B.V., All rights reserved.